These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 31446298

  • 1. Part 2: Physicochemical characterization of bevacizumab in 2 mg/mL antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate.
    Arvinte T, Palais C, Poirier E, Cudd A, Rajendran S, Brokx S, Dowd J.
    J Pharm Biomed Anal; 2019 Nov 30; 176():112802. PubMed ID: 31446298
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes.
    Zhang L, Yu L, Xu Y, Qin P, Shen P, Liu K, Fei M, Wang H, Cao Y, Lu L, Gao W, Zhang Z.
    Anal Bioanal Chem; 2023 Jul 30; 415(17):3341-3362. PubMed ID: 37162525
    [Abstract] [Full Text] [Related]

  • 4. Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach.
    Brown KA, Rajendran S, Dowd J, Wilson DJ.
    Drug Test Anal; 2019 Aug 30; 11(8):1207-1217. PubMed ID: 31041833
    [Abstract] [Full Text] [Related]

  • 5. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
    Seo N, Polozova A, Zhang M, Yates Z, Cao S, Li H, Kuhns S, Maher G, McBride HJ, Liu J.
    MAbs; 2018 Aug 30; 10(4):678-691. PubMed ID: 29553864
    [Abstract] [Full Text] [Related]

  • 6. Stability of infliximab solutions in different temperature and dilution conditions.
    Tokhadze N, Chennell P, Le Basle Y, Sautou V.
    J Pharm Biomed Anal; 2018 Feb 20; 150():386-395. PubMed ID: 29287266
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
    Hermosilla J, Sánchez-Martín R, Pérez-Robles R, Salmerón-García A, Casares S, Cabeza J, Cuadros-Rodríguez L, Navas N.
    BioDrugs; 2019 Apr 20; 33(2):193-205. PubMed ID: 30875076
    [Abstract] [Full Text] [Related]

  • 10. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev®), a bevacizumab biosimilar, under extended in-use conditions.
    Weiser S, Burns C, Zartler ER.
    J Oncol Pharm Pract; 2023 Jul 20; 29(5):1032-1043. PubMed ID: 35312402
    [Abstract] [Full Text] [Related]

  • 11. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity.
    Singh SK, Kumar D, Malani H, Rathore AS.
    Sci Rep; 2021 Jan 29; 11(1):2487. PubMed ID: 33514790
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
    Ruppen I, Beydon ME, Solís C, Sacristán D, Vandenheede I, Ortiz A, Sandra K, Adhikary L.
    Biologicals; 2021 Sep 29; 73():41-56. PubMed ID: 34593306
    [Abstract] [Full Text] [Related]

  • 14. Development and validation of aggregates analysis method in analytical similarity assessment of HLX04 vs Avastin®.
    Fei M, Zhang Q, Zhang L, Zhu X, Du C, Zhang Z.
    J Pharm Biomed Anal; 2023 Jan 20; 223():115121. PubMed ID: 36308924
    [Abstract] [Full Text] [Related]

  • 15. Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC.
    Reinders LMH, Klassen MD, Teutenberg T, Jaeger M, Schmidt TC.
    Anal Bioanal Chem; 2022 Sep 20; 414(23):6761-6769. PubMed ID: 35895102
    [Abstract] [Full Text] [Related]

  • 16. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
    Ruppen I, Beydon ME, Solís C, Sacristán D, Vandenheede I, Ortiz A, Sandra K, Adhikary L.
    Biologicals; 2022 Jun 20; 77():1-15. PubMed ID: 35667958
    [Abstract] [Full Text] [Related]

  • 17. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects.
    Wu X, Wynne C, Xu C, Gan Y, Wang C, Thomas BE, Yu JC, Li S, Zhang L.
    BioDrugs; 2019 Jun 20; 33(3):335-342. PubMed ID: 31016568
    [Abstract] [Full Text] [Related]

  • 18. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.
    Hettema W, Wynne C, Lang B, Altendorfer M, Czeloth N, Lohmann R, Athalye S, Schliephake D.
    Expert Opin Investig Drugs; 2017 Aug 20; 26(8):889-896. PubMed ID: 28651442
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
    Park D, Kim J, Yun J, Park SJ.
    Adv Ther; 2020 Oct 20; 37(10):4308-4324. PubMed ID: 32816233
    [Abstract] [Full Text] [Related]

  • 20. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
    Xu Y, Xie L, Zhang E, Gao W, Wang L, Cao Y, Xie MH, Jiang W, Liu S.
    MAbs; 2019 Apr 20; 11(3):606-620. PubMed ID: 30794092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.